SEC Form 4 · accession 0001479290-18-000060
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abhay Joshi
Officer — Chief Operating Officer
Period of report
Mar 21, 2018
Accepted (ET)
Mar 23, 2018 · 9:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 21, 2018 | M | 666 | $2.55 | A | 84,263 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1,F2 | $2.55 | Mar 21, 2018 | M | 666 | D | — | Apr 29, 2018 | Common Stock | 666 | 0 | D |
Explanation of responses
- F1This option was granted in connection with the Reporting Person's previous role as a consultant to the Issuer.
- F2The option is fully vested.